semaglutide after kidney transplant Anti-Obesity Drugs Benefit Recipients with Type 2 Diabetes Research shows semaglutide — commonly

10.1186/s12916-023-02753-6 76 ZhouH.-R.MaX.-F.LinW.-J.HaoM.YuX.-Y.LiH.-X.et al (2021)

J Pediatr Endocrinol Metab 2017;30(6):611622

First, Alzheimers disease and other dementias are strongly linked to metabolic dysfunctionespecially insulin resistance in the brain, sometimes labeled type 3 diabetes. Second, a class of diabetes and weight-management medicines called GLP-1 receptor agonists (GLP-1 RAs) shows early but increasingly consistent signals that they may lower dementia risk in people with type 2 diabetes, and possibly slow specific biological changes of Alzheimers in small clinical trials

When to Consult a Healthcare Professional While Semaglutide is an effective medication for managing type 2 diabetes and obesity, it is important for patients to recognize when its side effects warrant professional medical advice

In the closely watched trial, known as Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT), more than 17,000 people who were considered overweight or had obesity and who had cardiovascular disease but not diabetes took either semaglutide or a placebo for an average of nearly three years

BEL 1 Recommendation 5.4 Assess nontraditional ASCVD risk factors (Fig